AO Spine NA would like to congratulate Principal Investigator Michael Fehlings, MD (Department of Neurosurgery, University of Toronto) and his colleagues for the publication of the landmark study, Safety and Efficacy of Riluzole in Patients Undergoing Decompressive Surgery for Degenerative Cervical Myelopathy (CSM-Protect): A Multicentre Double-Blind, Placebo-Controlled, Randomised Phase 3 Trial, in The Lancet Neurology. 

Having their clinical study published in this highly respected journal demonstrates the importance of the research. Dr. Fehling's work was funded by AO Spine North America.